SAMSUNG PHARMACEUTICAL.CO (001360) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, SAMSUNG PHARMACEUTICAL.CO (001360) reported revenue of 46.1 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
202546.1 billion KRW-18.1 billion KRW11.5 billion KRW[source]
202444.3 billion KRW-14.8 billion KRW-14.1 billion KRW[source]
202352.0 billion KRW-18.0 billion KRW-24.8 billion KRW[source]
202251.8 billion KRW-14.0 billion KRW-25.1 billion KRW[source]
202154.9 billion KRW-18.1 billion KRW-40.3 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025167.4 billion KRW46.4 billion KRW121.0 billion KRW[source]
2024128.5 billion KRW22.6 billion KRW105.9 billion KRW[source]
202393.5 billion KRW15.9 billion KRW77.6 billion KRW[source]
2022117.9 billion KRW15.3 billion KRW102.6 billion KRW[source]
2021145.5 billion KRW18.2 billion KRW127.3 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice